Intellia Therapeutics (NTLA) Competitors

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Do institutionals & insiders have more ownership in NTLA or BEAM?

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has better earnings and valuation, NTLA or BEAM?

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$57.88M	21.58	-$519.02M	-$5.23	-2.31
Beam Therapeutics	$63.52M	32.85	-$376.74M	-$4.61	-4.50

Is NTLA or BEAM more profitable?

Beam Therapeutics has a net margin of -609.24% compared to Intellia Therapeutics' net margin of -1,154.10%. Beam Therapeutics' return on equity of -44.24% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-1,154.10%	-56.06%	-44.25%
Beam Therapeutics	-609.24%	-44.24%	-30.97%

Which has more risk and volatility, NTLA or BEAM?

Intellia Therapeutics has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.

Do analysts prefer NTLA or BEAM?

Intellia Therapeutics presently has a consensus price target of $33.37, suggesting a potential upside of 176.69%. Beam Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 134.94%. Given Intellia Therapeutics' higher probable upside, research analysts plainly believe Intellia Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
Beam Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	3.00

Does the media favor NTLA or BEAM?

In the previous week, Beam Therapeutics had 3 more articles in the media than Intellia Therapeutics. MarketBeat recorded 7 mentions for Beam Therapeutics and 4 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 0.48 beat Beam Therapeutics' score of 0.47 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Beam Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Beam Therapeutics beats Intellia Therapeutics on 12 of the 17 factors compared between the two stocks.